Maravai LifeSciences Files 8-K on Leadership Changes
Ticker: MRVI · Form: 8-K · Filed: Jun 9, 2025 · CIK: 1823239
| Field | Detail |
|---|---|
| Company | Maravai Lifesciences Holdings, Inc. (MRVI) |
| Form Type | 8-K |
| Filed Date | Jun 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, corporate-governance, filing
TL;DR
Maravai LifeSciences 8-K: Director departures, new elections, officer appointments, and comp plans filed June 9, 2025.
AI Summary
Maravai LifeSciences Holdings, Inc. filed an 8-K on June 9, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements/exhibits, with the earliest event reported as June 8, 2025.
Why It Matters
Changes in board composition and officer appointments can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Leadership changes and compensatory arrangements can introduce uncertainty and potential shifts in company direction.
Key Players & Entities
- MARAVAI LIFESCIENCES HOLDINGS, INC. (company) — Registrant
- June 8, 2025 (date) — Earliest event reported
- June 9, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 10770 Wateridge Circle Suite 200 San Diego, California 92121 (address) — Principal executive offices
FAQ
What specific items are being reported in this 8-K filing?
This 8-K reports on the departure of directors, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, along with Regulation FD disclosures and financial statements and exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is June 8, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on June 9, 2025.
What is the principal executive office address for Maravai LifeSciences Holdings, Inc.?
The principal executive office address is 10770 Wateridge Circle Suite 200, San Diego, California 92121.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI).